Manisit Das

Also affiliated with United Therapeutics (United States)

Immunology and MicrobiologyMedicineEngineeringMaterials Science

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth”.

Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth

Translational Oncology(2020)10.1016/j.tranon.2020.100856

N/A

0DataRank · unranked

16 citations

Xuefei Zhou, Yun Liu, Anirban Das, Benjamin G. Vincent, Jingjing Li +3 more

Nanotherapeutics for Immuno-Oncology: A Crossroad for New Paradigms

Trends in cancer(2020)10.1016/j.trecan.2020.01.011

N/A

0DataRank · unranked

37 citations

Manisit Das, Xuesi Chen, Wantong Song

Tumor neoantigen heterogeneity impacts bystander immune inhibition of pancreatic cancer growth

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.05.07.083352

N/A

0DataRank · unranked

4 citations

Xuefei Zhou, Yun Liu, Anirban Das, Benjamin G. Vincent, Jingjing Li +3 more

Nano-trapping CXCL13 reduces regulatory B cells in tumor microenvironment and inhibits tumor growth

Journal of Controlled Release(2022)10.1016/j.jconrel.2022.01.039

N/A

0DataRank · unranked

26 citations

Jingjing Li, Qi Liu, Manisit Das, Wantong Song, Xueqiong Zhang +7 more